Clinical Evidence For HAI Therapy For Colorectal Cancer Liver Metastases
Combined Hepatic Arterial Infusion Pump And Systemic Chemotherapy In The Modern Era For Chemotherapy-Naïve Patients With Unresectable Colorectal Liver Metastases
Verheij F, et al. | Annals of Surgical Oncology, 2023
A single-center, single-arm retrospective cohort study reported 62% of unresectable CRLM patients treated with first-line HAI therapy in combination with systemic chemotherapy achieved complete response or conversion to resection with 72% 5-Year Survival.
Prospective Phase II Trial Of Combination Hepatic Artery Infusion And Systemic Chemotherapy For Unresectable Colorectal Liver Metastases: Long Term Results And Curative Potential
Pak L, et al. | Journal of Surgical Oncology, 2018
A phase II, single-center study showed HAI therapy contributed to high response rate and 52% conversion to resection in heavily pre-treated unresectable patients with high tumor burden.
Hepatic Arterial Infusion In Combination With Modern Systemic Chemotherapy Is Associated With Improved Survival Compared With Modern Systemic Chemotherapy Alone In Patients With Isolated Unresectable Colorectal Liver Metastases: A Case–Control Study
Dhir M, et al. | Annals of Surgical Oncology, 2017
A case-control study at University of Pittsburgh Medical Center reported doubled median overall survival in patients with unresectable CRLM who received HAI Therapy in combination with modern systemic chemotherapy as 2nd or 3rd Line, whether or not conversion was achieved.
Perioperative Hepatic Arterial Infusion Pump Chemotherapy Is Associated With Longer Survival After Resection Of Colorectal Liver Metastases: A Propensity Score Analysis
Groot Koerkamp B, et al. | Journal of Clinical Oncology, 2017
A single-center, prospectively maintained database of 2,368 consecutive patients reported that HAI therapy in the adjuvant setting improved probability of "cure" (10-year overall survival) by 60%.
Hepatic Arterial Infusion Of Chemotherapy After Resection Of Hepatic Metastases From Colorectal Cancer
Kemeny N, et al. | New England Journal of Medicine, 1999
This randomized controlled trial showed that HAI therapy is the only adjuvant therapy for resected CRLM to significantly improve 2-year overall survival.